Anti-VEGF: Is Breast Always Best?
Drugs used to treat retinal disorders appear to pass into breast milk, posing a potential risk to the normal development of nursing infants
Maryam Mahdi | | Quick Read
Mothers are typically advised to breastfeed their newborns, but for those who live with medical conditions, managing the symptoms of their illnesses while nursing can present challenges. Research led by St. Michael’s Hospital in Toronto, Canada, indicates that the anti-vascular endothelial growth factor (anti-VEGF) drugs ranibizumab and aflibercept (injected intravitreally to treat retinal disease) are able to enter the breast milk of breastfeeding mothers, potentially raising concerns about possible adverse events in the developing infant (1). Notably, according to the labels on both drugs, it is unknown if the molecules are excreted in human breast milk.
Read the full article now
Log in or register to read this article in full and gain access to The Medicine Maker’s entire content archive. It’s FREE and always will be!
Or register now - it’s free and always will be!
You will benefit from:
- Unlimited access to ALL articles
- News, interviews & opinions from leading industry experts
- Receive print (and PDF) copies of The Medicine Maker magazine
Or Login via Social Media
By clicking on any of the above social media links, you are agreeing to our Privacy Notice.